Development of a perillyl alcohol topical cream formulation

Abhishek Gupta, Paul B Myrdal

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Perillyl alcohol (POH) is a relatively non-toxic agent that has been shown to be a promising anticancer monoterpene in preclinical models. Studies have indicated that topical application of POH may prove to be effective as a skin cancer chemoprevention therapy. The main aim of this study was to determine the influence of several factors on the stability of POH in solution and develop a topical formulation of POH. During preformulation, the influence of pH, temperature, ionic strength, and organic solvents, on the stability of POH was evaluated at four different temperatures: 4, 25, 37, and 48°C. POH was found to degrade under acidic conditions with degradation following apparent first-order kinetics. A hydrophilic topical cream formulation of POH was developed and prepared for toxicology and clinical studies. A reverse phase gradient HPLC method was developed to quantitate POH in the complex formulation. Stability studies of the formulation and a placebo were performed and the formulation was found to be physically and chemically stable over a period of 1 year at 4 and 25°C.

Original languageEnglish (US)
Pages (from-to)373-383
Number of pages11
JournalInternational Journal of Pharmaceutics
Volume269
Issue number2
DOIs
StatePublished - Jan 28 2004

Fingerprint

perilla alcohol
Monoterpenes
Temperature
Chemoprevention
Skin Neoplasms
Osmolar Concentration
Toxicology

Keywords

  • Perillyl alcohol
  • Reverse phase HPLC assay
  • Stability
  • Topical cream formulation

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Development of a perillyl alcohol topical cream formulation. / Gupta, Abhishek; Myrdal, Paul B.

In: International Journal of Pharmaceutics, Vol. 269, No. 2, 28.01.2004, p. 373-383.

Research output: Contribution to journalArticle

@article{8bd2468f97e8492ab2c8140fbf9b9be7,
title = "Development of a perillyl alcohol topical cream formulation",
abstract = "Perillyl alcohol (POH) is a relatively non-toxic agent that has been shown to be a promising anticancer monoterpene in preclinical models. Studies have indicated that topical application of POH may prove to be effective as a skin cancer chemoprevention therapy. The main aim of this study was to determine the influence of several factors on the stability of POH in solution and develop a topical formulation of POH. During preformulation, the influence of pH, temperature, ionic strength, and organic solvents, on the stability of POH was evaluated at four different temperatures: 4, 25, 37, and 48°C. POH was found to degrade under acidic conditions with degradation following apparent first-order kinetics. A hydrophilic topical cream formulation of POH was developed and prepared for toxicology and clinical studies. A reverse phase gradient HPLC method was developed to quantitate POH in the complex formulation. Stability studies of the formulation and a placebo were performed and the formulation was found to be physically and chemically stable over a period of 1 year at 4 and 25°C.",
keywords = "Perillyl alcohol, Reverse phase HPLC assay, Stability, Topical cream formulation",
author = "Abhishek Gupta and Myrdal, {Paul B}",
year = "2004",
month = "1",
day = "28",
doi = "10.1016/j.ijpharm.2003.09.026",
language = "English (US)",
volume = "269",
pages = "373--383",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Development of a perillyl alcohol topical cream formulation

AU - Gupta, Abhishek

AU - Myrdal, Paul B

PY - 2004/1/28

Y1 - 2004/1/28

N2 - Perillyl alcohol (POH) is a relatively non-toxic agent that has been shown to be a promising anticancer monoterpene in preclinical models. Studies have indicated that topical application of POH may prove to be effective as a skin cancer chemoprevention therapy. The main aim of this study was to determine the influence of several factors on the stability of POH in solution and develop a topical formulation of POH. During preformulation, the influence of pH, temperature, ionic strength, and organic solvents, on the stability of POH was evaluated at four different temperatures: 4, 25, 37, and 48°C. POH was found to degrade under acidic conditions with degradation following apparent first-order kinetics. A hydrophilic topical cream formulation of POH was developed and prepared for toxicology and clinical studies. A reverse phase gradient HPLC method was developed to quantitate POH in the complex formulation. Stability studies of the formulation and a placebo were performed and the formulation was found to be physically and chemically stable over a period of 1 year at 4 and 25°C.

AB - Perillyl alcohol (POH) is a relatively non-toxic agent that has been shown to be a promising anticancer monoterpene in preclinical models. Studies have indicated that topical application of POH may prove to be effective as a skin cancer chemoprevention therapy. The main aim of this study was to determine the influence of several factors on the stability of POH in solution and develop a topical formulation of POH. During preformulation, the influence of pH, temperature, ionic strength, and organic solvents, on the stability of POH was evaluated at four different temperatures: 4, 25, 37, and 48°C. POH was found to degrade under acidic conditions with degradation following apparent first-order kinetics. A hydrophilic topical cream formulation of POH was developed and prepared for toxicology and clinical studies. A reverse phase gradient HPLC method was developed to quantitate POH in the complex formulation. Stability studies of the formulation and a placebo were performed and the formulation was found to be physically and chemically stable over a period of 1 year at 4 and 25°C.

KW - Perillyl alcohol

KW - Reverse phase HPLC assay

KW - Stability

KW - Topical cream formulation

UR - http://www.scopus.com/inward/record.url?scp=0347990424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347990424&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2003.09.026

DO - 10.1016/j.ijpharm.2003.09.026

M3 - Article

VL - 269

SP - 373

EP - 383

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 2

ER -